FI106928B - Menetelmä terapeuttisesti käyttökelpoisen konjugaatin valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisen konjugaatin valmistamiseksi Download PDF

Info

Publication number
FI106928B
FI106928B FI923085A FI923085A FI106928B FI 106928 B FI106928 B FI 106928B FI 923085 A FI923085 A FI 923085A FI 923085 A FI923085 A FI 923085A FI 106928 B FI106928 B FI 106928B
Authority
FI
Finland
Prior art keywords
moiety
antibody
binds
ricin
cell
Prior art date
Application number
FI923085A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI923085A0 (fi
FI923085L (fi
Inventor
John Edward Fitton
Jan Holmgren
Andrew Firman Wright
David Charles Blakey
Peter Lind
Leif Lindholm
Original Assignee
Zeneca Ltd
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd, Kabi Pharmacia Ab filed Critical Zeneca Ltd
Publication of FI923085A0 publication Critical patent/FI923085A0/fi
Publication of FI923085L publication Critical patent/FI923085L/fi
Application granted granted Critical
Publication of FI106928B publication Critical patent/FI106928B/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44Antibodies bound to carriers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046Stomach, Intestines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)
  • Semiconductor Lasers (AREA)
  • Bipolar Transistors (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seasonings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI923085A 1991-07-03 1992-07-03 Menetelmä terapeuttisesti käyttökelpoisen konjugaatin valmistamiseksi FI106928B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919114399A GB9114399D0 (en) 1991-07-03 1991-07-03 Conjugates
GB9114399 1991-07-03

Publications (3)

Publication Number Publication Date
FI923085A0 FI923085A0 (fi) 1992-07-03
FI923085L FI923085L (fi) 1993-01-04
FI106928B true FI106928B (fi) 2001-05-15

Family

ID=10697775

Family Applications (1)

Application Number Title Priority Date Filing Date
FI923085A FI106928B (fi) 1991-07-03 1992-07-03 Menetelmä terapeuttisesti käyttökelpoisen konjugaatin valmistamiseksi

Country Status (24)

Country Link
EP (1) EP0528527B1 (de)
JP (1) JP3735379B2 (de)
KR (1) KR100252147B1 (de)
AT (1) ATE164768T1 (de)
AU (1) AU665546B2 (de)
CA (1) CA2073113C (de)
CZ (1) CZ209792A3 (de)
DE (1) DE69225035T2 (de)
DK (1) DK0528527T3 (de)
ES (1) ES2113923T3 (de)
FI (1) FI106928B (de)
GB (2) GB9114399D0 (de)
GR (1) GR3026575T3 (de)
HU (1) HU215243B (de)
IE (1) IE922190A1 (de)
IL (1) IL102399A (de)
MY (1) MY110513A (de)
NO (1) NO308539B1 (de)
NZ (1) NZ243437A (de)
PT (1) PT100660B (de)
SK (1) SK209792A3 (de)
TW (1) TW329425B (de)
ZA (1) ZA924973B (de)
ZW (1) ZW10192A1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5686121A (en) * 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
ATE68703T1 (de) 1984-02-08 1991-11-15 Cetus Corp Toxinkonjugate.
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
DE69122777T2 (de) * 1990-07-20 1997-04-10 Pharmacia & Upjohn Ab, Stockholm Zielgerichtete spezifische antikörper-superantigen konjugate und ihre präparation

Also Published As

Publication number Publication date
GB9114399D0 (en) 1991-08-21
JP3735379B2 (ja) 2006-01-18
JPH05320065A (ja) 1993-12-03
TW329425B (en) 1998-04-11
AU1943092A (en) 1993-01-07
MY110513A (en) 1998-07-31
EP0528527B1 (de) 1998-04-08
IL102399A (en) 2003-05-29
CA2073113A1 (en) 1993-01-04
DK0528527T3 (da) 1999-01-18
ZW10192A1 (en) 1993-03-31
NO308539B1 (no) 2000-09-25
ZA924973B (en) 1993-04-28
IE922190A1 (en) 1993-01-13
ES2113923T3 (es) 1998-05-16
IL102399A0 (en) 1993-01-14
SK209792A3 (en) 1994-06-08
PT100660A (pt) 1993-10-29
ATE164768T1 (de) 1998-04-15
CA2073113C (en) 2004-09-14
EP0528527A2 (de) 1993-02-24
NZ243437A (en) 1994-10-26
HU9202219D0 (en) 1992-10-28
FI923085A0 (fi) 1992-07-03
NO922383L (no) 1993-01-04
DE69225035D1 (de) 1998-05-14
EP0528527A3 (en) 1993-03-17
DE69225035T2 (de) 1998-08-13
KR100252147B1 (ko) 2000-09-01
GB9212880D0 (en) 1992-07-29
PT100660B (pt) 1999-06-30
HU215243B (hu) 1998-11-30
GR3026575T3 (en) 1998-07-31
KR930001928A (ko) 1993-02-22
CZ209792A3 (en) 1993-01-13
AU665546B2 (en) 1996-01-11
NO922383D0 (no) 1992-06-17
FI923085L (fi) 1993-01-04
HUT67048A (en) 1995-01-30

Similar Documents

Publication Publication Date Title
JP6728264B2 (ja) 抗her2抗体及びその結合体
US5840840A (en) Selective RNase cytotoxic reagents
DE69325577T2 (de) Mn-gen und protein
US7910100B2 (en) Antibodies directed to the mammalian EAG1 ion channel protein
US5608039A (en) Single chain B3 antibody fusion proteins and their uses
US5889157A (en) Humanized B3 antibody fragments, fusion proteins, and uses thereof
AU634314B2 (en) Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
AU2022335573A9 (en) Anti-nectin-4 antibody, drug conjugate, and preparation method therefor and use thereof
CN101602808B (zh) 特异性结合蛋白及其使用
WO2022001864A1 (zh) 一种抗体-药物偶联物,其制备方法及应用
EP4273169A1 (de) Entwicklung und verwendung eines funktionserweiterten antikörperblockierungsmittels
MX2012003996A (es) Anticuerpos que se unen especificamente al receptor epha2.
CN116472064A (zh) 抗体-药物偶联物及其应用
KR20230135653A (ko) 항-클라우딘 18.2 항체 및 이의 항체-약물 접합체
WO1992015327A1 (en) Recombinant double chain immunotoxins
WO2004076658A1 (ja) モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬
FI106928B (fi) Menetelmä terapeuttisesti käyttökelpoisen konjugaatin valmistamiseksi
Kokunai et al. Antigen related to cell proliferation in malignant gliomas recognized by a human monoclonal antibody
CN118307677B (zh) 一种针对间皮素的单克隆抗体及应用
US11020490B2 (en) Antibody-drug conjugate with a tubulysin analog warhead having a stabilized acetate group in the TUV subunit
CN120005018A (zh) 一种特异性靶向人sort1的抗体及其抗体偶联物
BR112016002752B1 (pt) Anticorpo ou seus fragmentos funcionais que pode especificamente se ligar ao her2, conjugados, composição farmacêutica, e, uso do anticorpo ou seus fragmentos funcionais, do conjugado ou da composição farmacêutica
BR122025011705A2 (pt) Anticorpo ou fragmento de ligação a antígeno, polipeptídeo, imunoconjugado, composição farmacêutica, uso dos anteriores, célula, bem como métodos para produção dos referidos anticorpo e polipeptídeo, e para inibição do crescimento de uma célula que expressa cd123

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: ZENECA LIMITED

MA Patent expired